Manhattan Genomics
Private Company
Funding information not available
Overview
Manhattan Genomics is an early-stage private biotech firm developing diagnostic genomic tests for personalized medicine and disease risk assessment. Founded in 2019, the company is positioned in the high-growth direct-to-consumer and clinical genomics markets. With limited public information, its current status is likely pre-revenue and in the technology development phase. Its success will hinge on validating its platform, securing regulatory approvals, and differentiating itself in a competitive landscape.
Technology Platform
Proprietary genomic analysis platform likely utilizing next-generation sequencing and bioinformatics for disease risk assessment and personalized medicine applications. Specific technical details are not public.
Opportunities
Risk Factors
Competitive Landscape
The genomic testing space is highly competitive. Manhattan Genomics would compete with DTC giants (23andMe, AncestryDNA), clinical diagnostic labs (Invitae, Myriad Genetics), large sequencing service providers, and numerous startups. Differentiation will require superior science, unique test offerings, or more accessible pricing.